Adaptogenics Eyes Peptide Market Shift as RFK Jr. Pushes Access Policy

U.S. Health Secretary Robert F. Kennedy Jr. has made his position clear: Americans are going to buy peptides regardless, so the government should ensure they come from inspected sources. That stance is driving a federal push toward an interim peptide access policy that would allow specialty pharmacies to produce certain peptides while formal rulemaking proceeds. The move could reshape how peptides reach patients, creating opportunities for pharmacies, telehealth platforms, and companies that offer more than standard ingredients. Adaptogenics (CSE: ADPT) is positioning itself for that shift, planning to develop delivery technologies to improve the stability, exposure, administration, and performance of selected peptides. The company has also acquired nutritional research assets from Berkwood Research to support a GLP-1 companion initiative. Kennedy outlined his case in a Fox News appearance this month, and the report cited estimates on the size of the peptide market. As policy opens pharmacy and telehealth channels, Adaptogenics aims to differentiate itself with advanced delivery and companion products.

For investors, the latest news and updates relating to ADPT are available in the company’s newsroom at https://nnw.fm/ADPT. The announcement was disseminated by NetworkNewsWire (“NNW”), a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team, NNW helps clients cut through information overload to achieve recognition and brand awareness.